General Clinical Chemistry Analyzers and Accessories
Abcam Sunitinib, Free base, 25MG
MW 398.5 Da, Purity >=99%. Sunitinib is a free base form of Sunitinib malate. A CSF-1 receptor kinase inhibitor .
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD-5069, 25MG
MW 476.5 Da, Purity >=98%. A potent and reversible CXCR2 chemokine receptor antagonist with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Umifenovir, 25MG
MW 477.4 Da, Purity >=95%. An indole derivative with broad-spectrum antiviral activity. It inhibits virus-mediated fusion with target membrane and blocks virus entry into target cells. It shows antiviral activity against many enveloped or non-enveloped RNA or DNA viruses with IC₅₀ values ranging from 0.41 to 16 uM. It (50 or 100 mg/kg/day) reduces mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Molecular dynamics and structural analysis show that Umifenovir may target SARS-CoV-2 spike glycoprotein and may block its trimerization which will reduce cell adherence and virus entry.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHZ868, 25MG
MW 423.4 Da, Purity >=98%. CHZ868 is a potent and selective type II JAK2 inhibitor (IC₅₀ = 110 nM). JAK2 and MPL mutant cell lines are sensitive to CHZ868, including type I JAK inhibitor persistent cells. CHZ868 displays significant activity in murine MPN models and induces reductions in mutant allele burden not observed with type I JAK inhibitors.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GL x -351322, 5MG
MW 431.5 Da, Purity >=98%. GLX-351322 is a potent NADPH oxidase-4 (NOX-4) inhibitor. Displays selectivity for NOX-4 over NOX-2. GLX-351322 inhibits hydrogen peroxide production from tetracycline inducible NOX4-overexpressing cells (IC₅₀ = 5 μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SP-2509, LSD1 inhibitor, 5MG
MW 437.9 Da, Purity >98%. Potent, selective (IC₅₀ = 13 nM) and reversible inhibitor of the histone demethylase LSD1 (KDM1A). No activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ABT-199 (Venetocla x ), Bcl-2 inhibitor., 1MG
MW 868.4 Da, Purity >98%. Potent, selective Bcl-2 inhibitor (Ki <0.01 nM) that inhibits the growth of Bcl-2–dependent tumors while sparing platelets. Bcl-2–specific BH3 mimetic. Promising agent in the treatment of chronic lymphocytic leukaemic and estrogen receptor-positive breast cancer.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 7-Cl-O-Nec1, metabolically stable RIP1 inhibitor, 5MG
MW 277.7 Da, Purity >98%. Necrostatin-1 (ab141053) analog with superior selectivity and metabolic stability in blocking RIP1. No off-target inhibition of indolamine-2,3-deoxygenase (IDO) in contrast to Necrostatin-1. Higher activity in inhibiting necroptosis in Jurkat cells than Necrostatin-1 (EC₅₀ = 210 nM vs. EC₅₀ = 490 nM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sonidegib (NVP-LDE225, Erismodegib), smoothened (Smo) antagonist, 50MG
MW 485.5 Da. Potent and selective Smoothened antagonist. Blocks Hedgehog signaling pathway activity (IC₅₀ = 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays. Anti-tumor activity in mouse medulloblastoma allograft model.
The product is subject to the following: Abcam Restricted Use Statement